Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13650022 | 0.89 | — | — | |
| SCHEMBL4018655 | 0.85 | LMNA (0.32) | LMNATHRBSMN1; SMN2HIF1AALDH1A1 | |
| SCHEMBL13725076 | 0.82 | LMNA (0.33) | LMNAALDH1A1 | |
| SCHEMBL13650025 | 0.79 | ALDH1A1 (0.33) | LMNAALDH1A1 | |
| SCHEMBL13650036 | 0.79 | LMNA (0.30) | LMNAALDH1A1 | |
| SCHEMBL13725935 | 0.76 | — | — | |
| SCHEMBL13839392 | 0.76 | — | — | |
| SCHEMBL13650039 | 0.76 | ENPP1 (0.32) | LMNAALDH1A1 | |
| SCHEMBL13839395 | 0.76 | ENPP1 (0.32) | LMNAALDH1A1 | |
| SCHEMBL13650024 | 0.76 | ALDH1A1 (0.36) | LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090253648-A1 | Tricyclic-Nucleoside Compounds for Treating Viral Infections | SMITHKLINE BEECHAM CORPORATION (US) | 2009-10-08 | — | — | US | disclosed |
| US-20090208457-A1 | Tricyclic-Nucleoside Prodrugs for Treating Viral Infections | SMITHKLINE BEECHAM CORPORATION (US) | 2009-08-20 | — | — | US | disclosed |
| US-7534771-B2 | Tricyclic-nucleoside prodrugs for treating viral infections | SMITHKLINE BEECHAM CORPORATION (US) | 2009-05-19 | — | — | US | disclosed |
| US-7524825-B2 | Tricyclic-nucleoside compounds for treating viral infections | SMITHKLINE BEECHAM CORPORATION (US) | 2009-04-28 | — | — | US | disclosed |
| US-20090048189-A1 | TRICYCLIC-NUCLEOSIDE COMPOUNDS FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. | 2009-02-19 | — | — | US | disclosed |
| US-20090048189-A1 | TRICYCLIC-NUCLEOSIDE COMPOUNDS FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048189-A1 | TRICYCLIC-NUCLEOSIDE COMPOUNDS FOR TREATING VIRAL INFECTIONS | TYMP, PNP, NSUN2 | LMNA 1445/4885THRB 3790/4885SMN1; SMN2 1123/4885 |
| US-20090208457-A1 | Tricyclic-Nucleoside Prodrugs for Treating Viral Infections | PNP, TYMP, HAVCR2 | LMNA 1318/4885THRB 3480/4885SMN1; SMN2 2148/4885 |
| US-20090253648-A1 | Tricyclic-Nucleoside Compounds for Treating Viral Infections | PNP, TYMP, NSUN2 | LMNA 974/4885THRB 3976/4885SMN1; SMN2 1248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.